Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
G GoliniR Fontana

Abstract

In order to further understanding of how different isolates of Burkholderia cepacia complex persist, spread and cause disease, B. cepacia-complex isolates from 60 patients attending the Cystic Fibrosis Centre of Verona, Italy, between 1997 and 2002 were analyzed. Strains were examined for species, presence of putative epidemic and virulence markers (i.e., cblA and the B. cepacia epidemic-strain marker [BCESM]), genetic relatedness and antibiotic susceptibility. Forty-five percent of patients were infected with B. cenocepacia recA subgroup B, 28% with B. cenocepacia recA subgroup A, 5% with B. multivorans and 5% with B. cepacia. No isolate carried cblA but 35% of B. cenocepacia and one of B. cepacia carried the BCESM transmissibility marker. Pulsed-field gel electrophoresis (PFGE) identified 40 types; 22 of these corresponded to sporadic isolates and 18 to clusters of identical or genetically related strains. Piperacillin, ceftazidime and piperacillin-tazobactam were the most active antibiotics (43.3, 31.1 and 35.5% of resistance, respectively). These results confirm the prevalence of B. cenocepacia in cystic fibrosis patients with rapid clinical deterioration and in those with stable cases of infection. The rates of multiple-so...Continue Reading

References

Dec 1, 1996·Journal of Medical Microbiology·J R GovanP Vandamme
Feb 3, 2000·Journal of Clinical Microbiology·E MahenthiralingamP Vandamme
Jul 4, 2001·American Journal of Respiratory and Critical Care Medicine·J J LiPumaE Mahenthiralingam
Mar 19, 2002·Emerging Infectious Diseases·David P SpeertEshwar Mahenthiralingam
Jun 7, 2003·Journal of Clinical Microbiology·Tom CoenyeEshwar Mahenthiralingam
Jul 29, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T J KiddC Coulter
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott A BernhardtJohn J LiPuma
Sep 6, 2003·Journal of Clinical Microbiology·Mónica V CunhaIsabel Sá-Correia

❮ Previous
Next ❯

Citations

Jul 5, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J H LeitãoI Sá-Correia
Aug 3, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M J Medina-PascualJ A Saéz-Nieto
Oct 21, 2006·Current Opinion in Pulmonary Medicine·Theodore G LiouBarbara C Cahill
Nov 13, 2019·Antimicrobial Agents and Chemotherapy·Mojgan Sabet, David C Griffith
Mar 17, 2015·Expert Review of Anti-infective Therapy·Vikas GautamAmit Agarwal
Oct 2, 2017·Medical Microbiology and Immunology·Priscila DentiniJosé Dirceu Ribeiro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The Journal of Antimicrobial Chemotherapy
David M Livermore
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
P Drevinek, Eshwar Mahenthiralingam
© 2021 Meta ULC. All rights reserved